Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 filgotinib plus csDMARDs in biologic-experienced rheumatoid arthritis
NL-OMON45679Phase 3Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in rheumatoid arthritis (RA) (3 arms), sponsored by Gilead Sciences. Primary endpoints: ACR20 response at Week 12, Safety and tolerability and 1 more. Planned start Jun 2017; status: withdrawn.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON45679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45679.